Caroline Pot

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


80 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2006 | 2005 | 2002 |
2024
 
Closing the scissor-shaped curve: Strategies to promote gender equality in academia.
Joyce J.A., Masina S., Michalik L., Pot C., Sempoux C., Amati F., 2024/03/14. Cell, 187 (6) pp. 1335-1342. Peer-reviewed.
[DOI][Pmid][serval:BIB_FEEC014C3937]
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Oechtering J., Stein K., Schaedelin S.A., Maceski A.M., Orleth A., Meier S., Willemse E., Qureshi F., Heijnen I., Regeniter A. et al., 2024/03. Neurology, 11 (2) pp. e200212. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8A3AEC81CECB]
 
Traitements de la sclérose en plaques en 2024.
Pot C., 2024/01/24. Revue medicale suisse, 20 (858) pp. 163-165. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_9E403AC3B03B]
 
Neurologie: ce qui a changé en 2023 [Neurology: what's new in 2023]
Pizzarotti B., Buhler-Heintze A., Allali G., Rouaud O., Bally J., Michel P., Hirt L., Théaudin M., Pot Kreis C., Ryvlin P. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 72-75. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_288F00E19F37]
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
Cagol A., Benkert P., Melie-Garcia L., Schaedelin S.A., Leber S., Tsagkas C., Barakovic M., Galbusera R., Lu P.J., Weigel M. et al., 2024/01/09. Neurology, 102 (1) pp. e207768. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83EF6BE319F6]
 
25-Hydroxycholesterol in health and diseases.
Nguyen C., Saint-Pol J., Dib S., Pot C., Gosselet F., 2024/01. Journal of lipid research, 65 (1) p. 100486. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5C500AA002A3]
 
Implication of Oxysterols and Phytosterols in Aging and Human Diseases
Vigne Solenne, Pot Caroline, 2024. pp. 231-260 dans Advances in Experimental Medicine and Biology, Springer International Publishing.
[DOI][WoS][Pmid][serval:BIB_52C11C8AB3E3]
2023
 
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.
Abdelhak A., Benkert P., Schaedelin S., Boscardin W.J., Cordano C., Oechtering J., Ananth K., Granziera C., Melie-Garcia L., Montes S.C. et al., 2023/12/01. JAMA neurology, 80 (12) pp. 1317-1325. Peer-reviewed.
[DOI][Pmid][serval:BIB_8ADA992C8122]
 
The Swiss Brain Health Plan 2023–2033
Bassetti Claudio L. A., Heldner Mirjam R., Adorjan Kristina, Albanese Emiliano, Allali Gilles, Arnold Marcel, Bègue Indrit, Bochud Murielle, Chan Andrew, do Cuénod Kim Q. et al., 2023/11/13. Clinical and Translational Neuroscience, 7 (4) p. 38.
[DOI][serval:BIB_CBDD6C3797BA]
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients.
Todea A.R., Melie-Garcia L., Barakovic M., Cagol A., Rahmanzadeh R., Galbusera R., Lu P.J., Weigel M., Ruberte E., Radue E.W. et al., 2023/09. Journal of magnetic resonance imaging, 58 (3) pp. 864-876. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FC74FD68A743]
 
Troubles cognitifs dans la sclérose en plaques : quand y penser ? [Cognitive impairment in multiple sclerosis: when to think about it?]
Perrenoud M., Blosch L., Du Pasquier R., Pot C., 2023/04/26. Revue medicale suisse, 19 (824) pp. 791-793. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_9A05F4407CED]
Endothelial cell-derived oxysterol ablation attenuates experimental autoimmune encephalomyelitis.
Ruiz F., Peter B., Rebeaud J., Vigne S., Bressoud V., Roumain M., Wyss T., Yersin Y., Wagner I., Kreutzfeldt M. et al., 2023/03/06. EMBO reports, 24 (3) pp. e55328. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_89C0C5C31546]
Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.
Mathias A., Pantazou V., Perriot S., Canales M., Jones S., Oberholster L., Moulin M., Fenwick C., Bernard-Valnet R., Théaudin M. et al., 2023/03. Neurology: Neuroimmunology & Neuroinflammation, 10 (2) pp. e200084. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_53DB58799AAF]
 
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
Meier S., Willemse EAJ, Schaedelin S., Oechtering J., Lorscheider J., Melie-Garcia L., Cagol A., Barakovic M., Galbusera R., Subramaniam S. et al., 2023/03/01. JAMA neurology, 80 (3) pp. 287-297. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A537F5BA3984]
The effects of time-restricted eating and weight loss on bone metabolism and health: a 6-month randomized controlled trial.
Papageorgiou M., Biver E., Mareschal J., Phillips N.E., Hemmer A., Biolley E., Schwab N., Manoogian ENC, Gonzalez Rodriguez E., Aeberli D. et al., 2023/02. Obesity, 31 Suppl 1 pp. 85-95. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AD823A124104]
 
Neurologie : ce qui a changé en 2022 [Neurology: what's new in 2022]
Bouvy C., Caranzano L., Allali G., Bally J., Benninger D., Beuchat I., Castro Jimenez M., Di Virgilio G., Hirt L., Michel P. et al., 2023/01/18. Revue medicale suisse, 19 (809-10) pp. 42-45. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_16DE2FC29F95]
2022
The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing.
Chiavi D., Haag C., Chan A., Kamm C.P., Sieber C., Stanikić M., Rodgers S., Pot C., Kesselring J., Salmen A. et al., 2022/11/10. JMIR medical informatics, 10 (11) pp. e37945. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6A65B18BA4CC]
Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry.
Stanikić M., Salmen A., Chan A., Kuhle J., Kaufmann M., Ammann S., Schafroth S., Rodgers S., Haag C., Pot C. et al., 2022/11. Multiple sclerosis and related disorders, 67 p. 104084. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C227A49D052]
 
Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study.
Sieber C., Chiavi D., Haag C., Kaufmann M., Horn A.B., Dressel H., Zecca C., Calabrese P., Pot C., Kamm C.P. et al., 2022/10/05. JMIR mHealth and uHealth, 10 (10) pp. e38709. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F4E200A2CF4B]
 
How Microbiota-Derived Metabolites Link the Gut to the Brain during Neuroinflammation.
Rebeaud J., Peter B., Pot C., 2022/09/04. International journal of molecular sciences, 23 (17) p. 10128. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E2B62AEA1BD0]
 
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A., Schaedelin S., Barakovic M., Benkert P., Todea R.A., Rahmanzadeh R., Galbusera R., Lu P.J., Weigel M., Melie-Garcia L. et al., 2022/07/01. JAMA neurology, 79 (7) pp. 682-692. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_77CA7B7F07E5]
 
Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
Borrelli S., Mathias A., Goff G.L., Pasquier R.D., Théaudin M., Pot C., 2022/07. Multiple sclerosis and related disorders, 63 p. 103887. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_356C04602C66]
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
Oechtering J., Lincke T., Schaedelin S., Décard B.F., Maceski A., Orleth A., Meier S., Willemse E., Buchmann A., Khalil M. et al., 2022/06. Annals of neurology, 91 (6) pp. 814-820. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D1EC8D7EE63A]
Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study.
Renaud C.O., Ziros P.G., Mathias A., Pot C., Sykiotis G.P., 2022/05/21. Antioxidants, 11 (5) p. 1015. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_089F1B91EF05]
Discussing Challenges in Diagnosis of Tuberculous Meningitis and Neurosarcoidosis.
Santos A., Desgranges F., Jovanovic M., Anichini A., Kritikos A., Dunet V., Brouland J.P., Théaudin M., Pot C., Du Pasquier R. et al., 2022/05. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 49 (3) pp. 445-451. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_971C2088FBE5]
 
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P., Meier S., Schaedelin S., Manouchehrinia A., Yaldizli Ö., Maceski A., Oechtering J., Achtnichts L., Conen D., Derfuss T. et al., 2022/03. The Lancet. Neurology, 21 (3) pp. 246-257. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F1DB0F9AA430]
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis.
Vigne S., Duc D., Peter B., Rebeaud J., Yersin Y., Ruiz F., Bressoud V., Collet T.H., Pot C., 2022/02/07. Journal of neuroinflammation, 19 (1) p. 42. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DBA41B63F47F]
Neurologie [Neurology : what's new in 2021]
Vicino A., Allali G., Bally J., Castro Jimenez M., Chiabotti Salvioni P., Hirt L., Hottinger A., Michel P., Novy J., Pot Kreis C. et al., 2022/01/19. Revue medicale suisse, 18 (764-5) pp. 51-55. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A713627E7914]
2021
 
Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a "common" first line treatment.
Pantazou V., Du Pasquier R., Pot C., Le Goff G., Théaudin M., 2021/10. Revue neurologique, 177 (8) pp. 935-940. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6D1705A76DD6]
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.
Oechtering J., Schaedelin S., Benkert P., Müller S., Achtnichts L., Vehoff J., Disanto G., Findling O., Fischer-Barnicol B., Orleth A. et al., 2021/09. Annals of neurology, 90 (3) pp. 477-489. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D94F4A25CF2E]
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
Maggi P., Kuhle J., Schädelin S., van der Meer F., Weigel M., Galbusera R., Mathias A., Lu P.J., Rahmanzadeh R., Benkert P. et al., 2021/08/10. Neurology, 97 (6) pp. e543-e553. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6A4C8678004D]
 
A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease.
Ruiz F., Wyss A., Rossel J.B., Sulz M.C., Brand S., Moncsek A., Mertens J.C., Roth R., Clottu A.S., Burri E. et al., 2021/08. British journal of pharmacology, 178 (16) pp. 3157-3175. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_98C0DB182F83]
 
The oxysterol receptor GPR183 in inflammatory bowel diseases.
Misselwitz B., Wyss A., Raselli T., Cerovic V., Sailer A.W., Krupka N., Ruiz F., Pot C., Pabst O., 2021/08. British journal of pharmacology, 178 (16) pp. 3140-3156. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EFBB171F53C5]
 
Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment.
Pantazou V., Pot C., Du Pasquier R., Le Goff G., Théaudin M., 2021/06. Multiple sclerosis and related disorders, 51 p. 102918. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F2127C696F5E]
 
The central vein sign in multiple sclerosis patients with vascular comorbidities.
Guisset F., Lolli V., Bugli C., Perrotta G., Absil J., Dachy B., Pot C., Théaudin M., Pasi M., van Pesch V. et al., 2021/06. Multiple sclerosis, 27 (7) pp. 1057-1065. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9846E746E94]
 
Comparison of non-parametric T<sub>2</sub> relaxometry methods for myelin water quantification.
Canales-Rodríguez E.J., Pizzolato M., Piredda G.F., Hilbert T., Kunz N., Pot C., Yu T., Salvador R., Pomarol-Clotet E., Kober T. et al., 2021/04. Medical image analysis, 69 p. 101959. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_99A4A4271BB8]
Neurologie [Recent Advances in Neurology]
Anichini A., Salvioni Chiabotti P., Bally J., Castro Jimenez M., Démonet J.F., Di Virgilio G., Hirt L., Hottinger A., Kuntzer T., Michel P. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 196-200. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_66C893415E17]
 
First-ever treatment in multiple sclerosis.
Pantazou V., Pot C., Du Pasquier R., Le Goff G., Théaudin M., 2021. Revue neurologique, 177 (1-2) pp. 93-99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4E341AFF275]
2020
An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets.
Zhang H., Madi A., Yosef N., Chihara N., Awasthi A., Pot C., Lambden C., Srivastava A., Burkett P.R., Nyman J. et al., 2020/11/24. Cell reports, 33 (8) p. 108433. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C1FBD0D08F65]
 
Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study.
Maggi P., Sati P., Nair G., Cortese ICM, Jacobson S., Smith B.R., Nath A., Ohayon J., van Pesch V., Perrotta G. et al., 2020/11. Annals of neurology, 88 (5) pp. 1034-1042. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9DFE2816DFA3]
Neurologie et COVID-19
Traore A., Pot C., Bonvin C., Wicki B., Alvarez V., 2020/05/06. Revue medicale suisse, 16 (692) pp. 947-949. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1E98435DBBB9]
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
Barin L., Kamm C.P., Salmen A., Dressel H., Calabrese P., Pot C., Schippling S., Gobbi C., Müller S., Chan A. et al., 2020/04. Multiple sclerosis, 26 (4) pp. 489-500. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_12D62389F084]
 
The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
Maggi P., Absinta M., Sati P., Perrotta G., Massacesi L., Dachy B., Pot C., Meuli R., Reich D.S., Filippi M. et al., 2020/04. Multiple sclerosis, 26 (4) pp. 421-432. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9EDD7CFD0B70]
 
Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis
Lysandropoulos Andreas P., Perrotta Gaetano, Billiet Thibo, Ribbens Annemie, Du Pasquier Renaud, Pot Caroline, Maggi Pietro, Théaudin Marie, 2020/03. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 47 (2) pp. 189-196.
[DOI][WoS][Pmid][serval:BIB_F1C137EF8B4B]
Rôle de la nutrition et de la flore intestinale dans les maladies autoimmunes - Que sait-on vraiment ? Représentation et connaissances scientifiques []
Pot C., 2020/01/29. Revue medicale suisse, 16 (679) pp. 184-185. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C7C84B87DA64]
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Kaufmann M., Puhan M.A., Salmen A., Kamm C.P., Manjaly Z.M., Calabrese P., Schippling S., Müller S., Kuhle J., Pot C. et al., 2020. Frontiers in neurology, 11 p. 156. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_12570E9CE817]
 
Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
Kamm C.P., Barin L., Gobbi C., Pot C., Calabrese P., Salmen A., Achtnichts L., Kesselring J., Puhan M.A., von Wyl V. et al., 2020/01. Journal of neurology, 267 (1) pp. 153-161. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_653FC3378648]
2019
Resolution of inflammation during multiple sclerosis.
Ruiz F., Vigne S., Pot C., 2019/11. Seminars in immunopathology, 41 (6) pp. 711-726. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_76A58CE69860]
 
Disrupting Myelin-Specific Th17 Cell Gut Homing Confers Protection in an Adoptive Transfer Experimental Autoimmune Encephalomyelitis.
Duc D., Vigne S., Bernier-Latmani J., Yersin Y., Ruiz F., Gaïa N., Leo S., Lazarevic V., Schrenzel J., Petrova T.V. et al., 2019/10/08. Cell reports, 29 (2) pp. 378-390.e4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6227A92C8D06]
Oxysterols in Autoimmunity.
Duc D., Vigne S., Pot C., 2019/09/12. International journal of molecular sciences, 20 (18). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5E37F576AD78]
The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis.
Wyss A., Raselli T., Perkins N., Ruiz F., Schmelczer G., Klinke G., Moncsek A., Roth R., Spalinger M.R., Hering L. et al., 2019/05. Mucosal immunology, 12 (3) pp. 733-745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_39C99B303D1E]
 
Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study.
Barin L., Kaufmann M., Salmen A., Kamm C.P., Gobbi C., Kuhle J., Pot C., Chan A., Czaplinski A., Ajdacic-Gross V. et al., 2019/02. Multiple sclerosis and related disorders, 28 pp. 17-25. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C8AB807A150A]
 
Intercellular Adhesion Molecule-1 (ICAM-1) and ICAM-2 Differentially Contribute to Peripheral Activation and CNS Entry of Autoaggressive Th1 and Th17 Cells in Experimental Autoimmune Encephalomyelitis.
Haghayegh Jahromi N., Marchetti L., Moalli F., Duc D., Basso C., Tardent H., Kaba E., Deutsch U., Pot C., Sallusto F. et al., 2019. Frontiers in immunology, 10 p. 3056. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DCBA17B192C4]
2018
 
The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
Barin L., Salmen A., Disanto G., Babačić H., Calabrese P., Chan A., Kamm C.P., Kesselring J., Kuhle J., Gobbi C. et al., 2018/10. Multiple sclerosis and related disorders, 25 pp. 112-121. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_879A4B0BCAE5]
The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research.
Steinemann N., Kuhle J., Calabrese P., Kesselring J., Disanto G., Merkler D., Pot C., Ajdacic-Gross V., Rodgers S., Puhan M.A. et al., 2018/08/13. BMC neurology, 18 (1) p. 111. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_731102C07BFD]
Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.
Kaufmann M., Kuhle J., Puhan M.A., Kamm C.P., Chan A., Salmen A., Kesselring J., Calabrese P., Gobbi C., Pot C. et al., 2018. Multiple sclerosis journal - experimental, translational and clinical, 4 (4) p. 2055217318814562. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1C178259543F]
2017
Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.
Lalive P.H., Kreutzfeldt M., Devergne O., Metz I., Bruck W., Merkler D., Pot C., 2017/07/24. Journal of neuroinflammation, 14 (1) p. 144. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F28D2598286B]
 
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G., Barro C., Benkert P., Naegelin Y., Schädelin S., Giardiello A., Zecca C., Blennow K., Zetterberg H., Leppert D. et al., 2017/06. Annals of neurology, 81 (6) pp. 857-870. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AF816780909]
EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis.
Clottu A.S., Mathias A., Sailer A.W., Schluep M., Seebach J.D., Du Pasquier R., Pot C., 2017/01/03. Cell reports, 18 (1) pp. 213-224. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C112D80A9534]
 
IL-27-Induced Type 1 Regulatory T-Cells Produce Oxysterols that Constrain IL-10 Production.
Vigne S., Chalmin F., Duc D., Clottu A.S., Apetoh L., Lobaccaro J.A., Christen I., Zhang J., Pot C., 2017. Frontiers in immunology, 8 p. 1184. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CCD579415CF9]
2016
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Disanto G., Benkert P., Lorscheider J., Mueller S., Vehoff J., Zecca C., Ramseier S., Achtnichts L., Findling O., Nedeltchev K. et al., 2016. Plos One, 11 (3) pp. e0152347. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745A35B87D48]
2015
 
IL-27 Induces Th17 Differentiation in the Absence of STAT1 Signaling.
Peters A., Fowler K.D., Chalmin F., Merkler D., Kuchroo V.K., Pot C., 2015. Journal of Immunology, 195 (9) pp. 4144-4153. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_535CBA631B4D]
 
Oxysterols regulate encephalitogenic CD4(+) T cell trafficking during central nervous system autoimmunity.
Chalmin F., Rochemont V., Lippens C., Clottu A., Sailer A.W., Merkler D., Hugues S., Pot C., 2015/01. Journal of autoimmunity, 56 pp. 45-55. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2476A4171D41]
2014
 
Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression.
Guéry L., Dubrot J., Lippens C., Brighouse D., Malinge P., Irla M., Pot C., Reith W., Waldburger J.M., Hugues S., 2014/11/15. Cancer research, 74 (22) pp. 6430-6440. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A2B80E4B8BB3]
2013
 
Fine tuning of the immune response by the Aryl Hydrocarbon Receptor
Pot Caroline, Quintana Francisco J., Kuchroo Vijay K., 2013/11. Seminars in Immunopathology, 35 (6) pp. 613-613.
[DOI][WoS][serval:BIB_B12950BE3746]
 
Metallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiation.
Wu C., Pot C., Apetoh L., Thalhamer T., Zhu B., Murugaiyan G., Xiao S., Lee Y., Rangachari M., Yosef N. et al., 2013/05/07. Proceedings of the National Academy of Sciences of the United States of America, 110 (19) pp. 7802-7807. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DD5D275B55BE]
 
Nogo-A downregulation improves insulin secretion in mice.
Bonal C.B., Baronnier D.E., Pot C., Benkhoucha M., Schwab M.E., Lalive P.H., Herrera P.L., 2013/05. Diabetes, 62 (5) pp. 1443-1452. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DBF3306E4D52]
 
SOCS3 Transactivation by PPARγ Prevents IL-17-Driven Cancer Growth.
Berger H., Végran F., Chikh M., Gilardi F., Ladoire S., Bugaut H., Mignot G., Chalmin F., Bruchard M., Derangère V. et al., 2013. Cancer Research, 73 (12) pp. 3578-3590. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8768846D2B6D]
2012
 
Aryl hydrocarbon receptor controls regulatory CD4+ T cell function.
Pot C., 2012. Swiss medical weekly, 142 pp. w13592. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4887BAEE2676]
2011
 
Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27.
Pot C., Apetoh L., Awasthi A., Kuchroo V.K., 2011/12. Seminars in immunology, 23 (6) pp. 438-445. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BEDD47445C8]
 
Type 1 regulatory T cells (Tr1) in autoimmunity.
Pot C., Apetoh L., Kuchroo V.K., 2011/06. Seminars in immunology, 23 (3) pp. 202-208. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1CDC69B32FCA]
2010
 
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27.
Apetoh L., Quintana F.J., Pot C., Joller N., Xiao S., Kumar D., Burns E.J., Sherr D.H., Weiner H.L., Kuchroo V.K., 2010/09. Nature immunology, 11 (9) pp. 854-861. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0CFC7441F593]
 
Molecular pathways in the induction of interleukin-27-driven regulatory type 1 cells.
Pot C., Apetoh L., Awasthi A., Kuchroo V.K., 2010/06. Journal of interferon & cytokine research, 30 (6) pp. 381-388. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BD6D5F321010]
2009
 
Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells.
Pot C., Jin H., Awasthi A., Liu S.M., Lai C.Y., Madan R., Sharpe A.H., Karp C.L., Miaw S.C., Ho I.C. et al., 2009/07/15. Journal of immunology, 183 (2) pp. 797-801. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F88EFC0BECB]
 
Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells.
Awasthi A., Riol-Blanco L., Jäger A., Korn T., Pot C., Galileos G., Bettelli E., Kuchroo V.K., Oukka M., 2009/05/15. Journal of immunology, 182 (10) pp. 5904-5908. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F389524E2899]
2008
 
Human herpesvirus-6 variant A encephalomyelitis.
Pot C., Burkhard P.R., Villard J., Perrin L., Kaiser L., Landis T., Lalive P.H., 2008/03/18. Neurology, 70 (12) pp. 974-976. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBFC2C27E814]
2006
 
Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy.
Pot C., Chizzolini C., Vokatch N., Tiercy J.M., Ribi C., Landis T., Perren F., 2006/09. Archives of neurology, 63 (9) pp. 1318-1320. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_54BD6954B2D5]
 
Synaptic destabilization by neuronal Nogo-A.
Aloy E.M., Weinmann O., Pot C., Kasper H., Dodd D.A., Rülicke T., Rossi F., Schwab M.E., 2006/06. Brain cell biology, 35 (2-3) pp. 137-156. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30C9EDC946D0]
2005
 
Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot C., Oppliger R., Castillo V., Coeytaux A., Hauser C., Burkhard P.R., 2005/01/25. Neurology, 64 (2) pp. 392-393. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1C5E1FA6DFDA]
2002
 
Nogo-A expressed in Schwann cells impairs axonal regeneration after peripheral nerve injury.
Pot C., Simonen M., Weinmann O., Schnell L., Christ F., Stoeckle S., Berger P., Rülicke T., Suter U., Schwab M.E., 2002/10/14. The Journal of cell biology, 159 (1) pp. 29-35. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_41B91F37631E]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University